Adlai Nortye News, Adlai Nortye Quote, ANL Quote

Adlai Nortye (NQ:ANL) Delayed: 10.58 --0 (-0%)

Prev. Close

$10.58

Today 6M 1Y 5Y

Open

$10.55

52 Wk High

$22.89

52 Wk Low

$1.85

Day High

$10.65

Day Low

$10.30

P/E

N/A

EPS

$-0.06

Volume

79,539

Friends, Peers and Foes (?): BNAI, DBRG SOPA (more...)

ALERTS | RSS

Oct 15, 2026 07:00 AM Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Oct 1, 2026 10:04 AM Form 4 Adlai Nortye Group Ltd. For: Sep 29 Filed by: Ji Ping
Sep 30, 2026 07:00 AM Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
Sep 24, 2026 11:09 AM Form 4 Adlai Nortye Group Ltd. For: Sep 22 Filed by: Ji Ping
Sep 22, 2026 02:00 PM Form 424B3 Adlai Nortye/ADR
Sep 10, 2026 06:10 AM Jefferies Starts Adlai Nortye Ltd. (ANL) at Buy
Sep 8, 2026 07:01 AM Adlai Nortye doses first patient in AN4035 global Phase I trial
Sep 8, 2026 07:00 AM Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
Sep 8, 2026 06:36 AM Lucid Capital Markets Starts Adlai Nortye Ltd. (ANL) at Buy
Aug 26, 2026 04:28 PM Form 4 Adlai Nortye Group Ltd. For: Aug 24 Filed by: Ye Xiaofeng

Entities mentioned with ANL

View All Entities